Capturing Patient Value in an Economic Evaluation

Abstract

ObjectiveEconomic evaluations predominantly use generic outcomes, such as the Euro Quality of Life‐5 Dimension (EQ‐5D), to assess health status. However, because of the generic nature, they are less suitable to capture the quality of life of patients with specific conditions. Given the transition to patient‐centered (remote) care delivery, this study aims to evaluate the possibility of using disease‐specific measures in a cost‐effectiveness analysis.MethodsA real‐life cohort from Maasstad Hospital (2020–2021) in the Netherlands, with 772 patients with rheumatoid arthritis (RA), was used to assess the cost‐effectiveness of electronic consultations (e‐consultations) compared with face‐to‐face consultations. The Incremental Cost‐Effectiveness Ratio (ICER), based on the generic EQ‐5D, was compared with ICER's based on RA‐specific measures: the Rheumatoid Arthritis Impact of Disease (RAID) and Health Assessment Questionnaire‐Disability Index (HAQ‐DI). To compare the cost‐effectiveness of these different measures, HAQ‐DI and RAID were expressed in quality‐adjusted life‐years (QALYs) via estimated conversion equations.ResultsDisease‐specific patient‐reported outcome measures (PROMs) offer a promising alternative for traditional measures in economic evaluations, capturing patient‐relevant domains more comprehensively. Because PROMs are increasingly applied in clinical practice, the next step entails modeling of an RA patient‐wide conversion equation to implement PROMs in economic evaluations.ConclusionThe conventional ICER (eg, EQ‐5D) indicates that e‐consultations are cost‐effective with cost savings of −€161,000 per QALY gained for a prevalent RA cohort treated in a secondary trainee hospital. RA‐specific measures show similar results, with ICERs of −€163,000 per HAQ‐DI (QALY) and −€223,000 per RAID (QALY) gained. RA‐specific measures capture patient‐relevant domains and offer the opportunity to improve the assessment and treatment of the disease impact.